Cti Biopharma reported $30.46M in Operating Expenses for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Expenses Change
Baxter International BAX:US USD 6.57B 3.18B
Bristol Myers Squibb BMY:US USD 9.46B 716M
Cti Biopharma CTIC:US USD 30.46M 753K
Cytori Therapeutics CYTX:US USD 5.17M 47K
Eli Lilly And LLY:US USD 5.47B 200.3M
Geron GERN:US USD 40.24M 12.2M
Mirati Therapeutics MRTX:US USD 191.87M 9.31M
Northwest Biotherapeutics NWBO:US USD 16.28M 5.41M
Novartis NOVN:VX USD 11.05B 378M
Novartis NVS:US USD 11.05B 378M
Seattle Genetics SGEN:US USD 703.1M 72.49M
Teva Pharmaceutical Industries TEVA:US USD 3.18B 1.56B
YTE INCY:US USD 684.93M 27.96M